unicar02-t-ppsma
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 16, 2020 (NCT04633148)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04633148 | Phase 1 | Nov 16, 2020 | Cellex Patient Treatment GmbH, Institut fur Klinische Forschung, Germany, Julius-Maximilians University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellex Patient Treatment GmbH | For profit | 1 | 1 | 1 | 2020 |
| Institut fur Klinische Forschung, Germany | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Julius-Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1